As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to becoming an oncology powerhouse. | More than 4 years after its first ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK ...